AU2004209986C1 - Partial and full agonists of A1 adenosine receptors - Google Patents

Partial and full agonists of A1 adenosine receptors Download PDF

Info

Publication number
AU2004209986C1
AU2004209986C1 AU2004209986A AU2004209986A AU2004209986C1 AU 2004209986 C1 AU2004209986 C1 AU 2004209986C1 AU 2004209986 A AU2004209986 A AU 2004209986A AU 2004209986 A AU2004209986 A AU 2004209986A AU 2004209986 C1 AU2004209986 C1 AU 2004209986C1
Authority
AU
Australia
Prior art keywords
amino
oxolan
hydroxymethyl
hydroxy
purin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004209986A
Other languages
English (en)
Other versions
AU2004209986A1 (en
AU2004209986B2 (en
Inventor
Gloria Cristalli
Venkata Palle
Jeff Zablocki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Palo Alto Inc
Original Assignee
Gilead Palo Alto Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Palo Alto Inc filed Critical Gilead Palo Alto Inc
Publication of AU2004209986A1 publication Critical patent/AU2004209986A1/en
Publication of AU2004209986B2 publication Critical patent/AU2004209986B2/en
Application granted granted Critical
Publication of AU2004209986C1 publication Critical patent/AU2004209986C1/en
Assigned to GILEAD PALO ALTO, INC. reassignment GILEAD PALO ALTO, INC. Request to Amend Deed and Register Assignors: CV THERAPEUTICS, INC.
Assigned to GILEAD PALO ALTO, INC. reassignment GILEAD PALO ALTO, INC. Request to Amend Deed and Register Assignors: CV THERAPEUTICS, INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AU2004209986A 2003-02-03 2004-02-02 Partial and full agonists of A1 adenosine receptors Ceased AU2004209986C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44452603P 2003-02-03 2003-02-03
US60/444,526 2003-02-03
PCT/US2004/002868 WO2004069185A2 (en) 2003-02-03 2004-02-02 Partial and full agonists of a1 adenosine receptors

Publications (3)

Publication Number Publication Date
AU2004209986A1 AU2004209986A1 (en) 2004-08-19
AU2004209986B2 AU2004209986B2 (en) 2009-01-22
AU2004209986C1 true AU2004209986C1 (en) 2009-08-13

Family

ID=32850877

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004209986A Ceased AU2004209986C1 (en) 2003-02-03 2004-02-02 Partial and full agonists of A1 adenosine receptors

Country Status (8)

Country Link
US (1) US7163928B2 (enExample)
EP (1) EP1590359A2 (enExample)
JP (1) JP2006516641A (enExample)
KR (1) KR20050097971A (enExample)
AU (1) AU2004209986C1 (enExample)
CA (1) CA2515068A1 (enExample)
NZ (1) NZ541651A (enExample)
WO (1) WO2004069185A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7371737B2 (en) 2004-09-09 2008-05-13 Solvay Pharmaceuticals, B.V. 2-substituted-6-trifluoromethyl purine derivatives with adenosine-A3 antagonistic activity
US7338964B2 (en) 2004-09-09 2008-03-04 Solvay Pharmaceuticals, B.V. 2-substituted-1-deaza purine derivatives with adenosine receptor modulating activity
AR050630A1 (es) * 2004-09-09 2006-11-08 Solvay Pharm Bv DERIVADOS DE 6- TRIFLUOROMETIL PURINA 2- SUSTITUIDA CON ACTIVIDAD ANTAGONISTA DE ADENOSINA-A3. PROCESOS DE OBTENCIoN Y COMPOSICIONES FARMACÉUTICAS.
US7488720B2 (en) 2005-10-13 2009-02-10 Cv Therapeutics, Inc. A1 adenosine receptor agonists
BRPI0619261A2 (pt) * 2005-11-30 2011-09-27 Inotek Pharmaceuticals Corp derivados de purina e métodos de uso desses
KR101204213B1 (ko) 2007-12-21 2012-11-26 에프. 호프만-라 로슈 아게 오렉신 수용체 길항제로서의 헤테로아릴 유도체
ATE535515T1 (de) 2008-01-11 2011-12-15 Hoffmann La Roche Modulatoren für amyloid beta
KR101247840B1 (ko) 2008-02-22 2013-03-26 에프. 호프만-라 로슈 아게 아밀로이드 베타 조절제
JP5502089B2 (ja) 2008-10-09 2014-05-28 エフ．ホフマン−ラ ロシュ アーゲー アミロイドβのモジュレーター
CN102209537A (zh) 2008-11-10 2011-10-05 弗·哈夫曼-拉罗切有限公司 杂环γ分泌酶调节剂
EP2448953A1 (en) 2009-06-30 2012-05-09 Forest Laboratories Holdings Limited Alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thatreof as a2ar agonists
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
AR131380A1 (es) 2022-12-16 2025-03-12 Astrazeneca Ab Purinas 2,6,9-trisustituidas

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3346560A (en) * 1965-01-29 1967-10-10 Merck & Co Inc Purine 3-deoxynucleosides
JPS55160796A (en) * 1979-06-01 1980-12-13 Yamasa Shoyu Co Ltd Preparation of n6-alkyl cordycepin
JPS55160794A (en) * 1979-06-01 1980-12-13 Yamasa Shoyu Co Ltd N6-substituted cordycepin and its preparation
AU575438B2 (en) 1984-10-26 1988-07-28 Warner-Lambert Company N6 - substituted deoxyribose analogues of adenosines
US5432164A (en) * 1991-10-24 1995-07-11 Novo Nordisk A/S C2,N6 -disubstituted adenosine derivatives
US5688774A (en) * 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
AU3255097A (en) * 1996-07-05 1998-02-02 Novo Nordisk A/S Novel (n)-alkoxyadenine derivatives acting as cytokine inhibitors
US5789416B1 (en) 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
AU5584698A (en) * 1996-10-30 1998-05-22 University Of North Carolina At Chapel Hill, The P2y receptor antagonists
WO1998050047A1 (en) * 1997-05-09 1998-11-12 Trustees Of The University Of Pennsylvania Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
AU1363699A (en) * 1997-10-23 1999-05-10 National Institute Of Health Methods for reducing ischemic injury of the heart via the sequential administ ration of monophosphoryl lipid a and adenosine receptor agents
GB9723590D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723589D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723566D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
AU3080899A (en) * 1998-03-11 1999-09-27 Lipitek International, Inc. Novel nucleoside analogs and uses in treating disease
GB9813554D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
US6605597B1 (en) 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
US6258793B1 (en) 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
CA2508479A1 (en) * 2002-12-03 2004-06-17 Baylor University Compounds resistant to metabolic deactivation and methods of use

Also Published As

Publication number Publication date
EP1590359A2 (en) 2005-11-02
AU2004209986A1 (en) 2004-08-19
US20040198691A1 (en) 2004-10-07
US7163928B2 (en) 2007-01-16
AU2004209986B2 (en) 2009-01-22
KR20050097971A (ko) 2005-10-10
NZ541651A (en) 2009-01-31
WO2004069185A3 (en) 2004-09-23
CA2515068A1 (en) 2004-08-19
JP2006516641A (ja) 2006-07-06
WO2004069185A2 (en) 2004-08-19

Similar Documents

Publication Publication Date Title
AU2008249143B2 (en) Partial and full agonists of A1 adenosine receptors
AU2002327426B2 (en) Adenosine A3 receptor agonists
US20090156544A1 (en) A1 adenosine receptor agonists
AU2004209986B2 (en) Partial and full agonists of A1 adenosine receptors
JP5042996B2 (ja) Ａ１アデノシンレセプターアゴニスト
US6946449B2 (en) Partial and full agonists of A1 adenosine receptors
US7157440B2 (en) Partial and full agonists of A1 adenosine receptors
US20090137520A1 (en) A1 adenosine receptor agonists
HK1130805A (en) Partial and full agonists of a1 adenosine receptors

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 23 MAR 2009.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 23 MAR 2009

FGA Letters patent sealed or granted (standard patent)
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PATENTEE NAME FROM CV THERAPEUTICS, INC. TO GILEAD PALO ALTO, INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired